IL1B and atherosclerosis: Taken together, these results suggest that anakinra inhibits the functions of IL-1, thereby reducing proinflammatory cytokine release and inflammatory cell recruitment, decreasing plaque size, and stabilizing the lipid-laden plaques, therefore, anakinra inhibits almost all stages of atherosclerosis.